再鼎醫藥-SB(09688.HK)發售價確定為每股562港元 募集資金59.37億港元
格隆匯9月22日丨再鼎醫藥-SB(09688.HK)公佈,國際發售與香港公開發售的最終發售價均已確定為每股562港元。待香港聯交所批准後,股份預期將於2020年9月28日在香港聯交所主板開始交易。
公司來自全球發售的所得款項總額預計約為59.37億港元。公司計劃將全球發售的所得款項淨額用於分配至與核心產品相關的研發工作,並提升核心產品的商業化能力;為進行中及計劃臨牀試驗以及管線中其他候選藥物的準備中註冊備案撥資;探索新的全球授權及合作機會並引進具有臨牀驗證的潛在全球同類最佳╱同類首創資產,並與公司當前產品管線形成協同效應及與公司的專業知識保持一致;持續投資及擴大公司的內部研發產品管線以及在全球招聘及培訓高端人才;為營運資金及其他一般企業用途撥資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.